Evidence map›Paper›PMID 35248529›Full record

ArticleNeuropharmacology2022

Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome.

Sheryl Anne D Vermudez, Aditi Buch, Kelly Weiss, Rocco G Gogliotti, Colleen M Niswender

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Reciprocal regulation of the HbioRxiv : the preprint server for biology · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sheryl Anne D VermudezDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, 37232, USA.
Aditi BuchDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, 37232, USA.
Kelly WeissDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, 37232, USA.
Rocco G GogliottiDepartment of Molecular Pharmacology and Neuroscience, Loyola University Chicago, IL, 60660, USA.
Colleen M NiswenderDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, 37232, USA; Vanderbilt Kennedy Center, Vanderbilt University, Nashville, TN, 37232, USA; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, 37232, USA; Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, 37232, USA. Electronic address: Colleen.niswender@vanderbilt.edu.
Vanderbilt University · USLoyola University Chicago · US

Funding

TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2M
REGULATION OF SIGNALING BY MGLUR5R01MH062646 · NIMH · VANDERBILT UNIVERSITY · PI P Jeffrey Conn, COLLEEN M NISWENDER · 2001 to 2026
$10.9M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lea K Davis · 2020 to 2026
$10.3M
A precision medicine approach to Rett SyndromeR01NS112171 · NINDS · LOYOLA UNIVERSITY CHICAGO · PI GOGLIOTTI, ROCCO GEORGE · 2020 to 2024
$1.7M
Normalizing E:I imbalance in Rett Syndrome by Modulation of Late Response GenesK01MH112983 · NIMH · VANDERBILT UNIVERSITY · PI GOGLIOTTI, ROCCO GEORGE · 2017 to 2020
$543k
Stratifying Rett syndrome patient populations to evaluate the efficacy of genetic and pharmacological therapeutic interventionsF31MH119699 · NIMH · VANDERBILT UNIVERSITY · PI VERMUDEZ, SHERYL ANNE DAGUIMOL · 2019 to 2021
$91k
NICHD NIH HHS P50 HD103537NIGMS NIH HHS T32 GM007628NIMH NIH HHS F31 MH119699NIMH NIH HHS K01 MH112983NIMH NIH HHS R01 MH062646NINDS NIH HHS R01 NS112171
6 · The paper itself

Abstract

Rett syndrome (RTT) and MECP2 Duplication syndrome (MDS) have opposing molecular origins in relation to expression and function of the transcriptional regulator Methyl-CpG-binding protein 2 (MeCP2). Several clinical and preclinical phenotypes, however, are shared between these disorders. Modulation of MeCP2 levels has recently emerged as a potential treatment option for both of these diseases. However, toxicity concerns remain with these approaches. Here, we focus on pharmacologically modulating the group II metabotropic glutamate receptors (mGlu), mGlu

Indexed as

Receptors, Metabotropic GlutamateRett SyndromeX-Linked Intellectual DisabilityAnimalsDisease Models, AnimalHumansMethyl-CpG-Binding Protein 2MiceMice, Inbred C57BLMice, KnockoutMecp2 protein, mouseMethyl-CpG-Binding Protein 2Receptors, Metabotropic GlutamateMECP2MECP2 duplication syndromemGlu(2)mGlu(3)Rett syndromeTrace fear

Identifiers

PMID35248529
PMCPMC8973998
OpenAlexW4214832903

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.